Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism FAK inhibitors(Focal adhesion kinase inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Preclinical | - | 07 Feb 2024 | |
Solid tumor | Preclinical | - | 07 Feb 2024 | |
Pulmonary Fibrosis | Preclinical | - | - | |
Pulmonary Fibrosis | Preclinical | - | - | |
Pulmonary Fibrosis | Preclinical | - | - |